Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9631023
APP PUB NO 20160272719A1
SERIAL NO

15080020

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to the field of glycosylation engineering of proteins. More particularly, the present invention relates to glycosylation engineering to generate proteins with improved therapeutic properties, including antibodies with increased antibody-dependent cellular cytotoxicity.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
ROCHE GLYCART AGWAGISTRASSE 18 SCHLIEREN 8952

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Bailey, James E Zurich, CH 30 1601
Jean-Mairet, Joël Barcelona, ES 16 219
Umaña, Pablo Zurich, CH 95 705

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Oct 25, 2028
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00